

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for rituximab products under the patient's prescription drug benefit.

Description:

This is a regulatory policy for rituximab products applicable to the state of Maryland.

Applicable Drug List:

Riabni Rituxan Ruxience Truxima

Policy/Guideline:

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

Authorization may be granted when the patient has a diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.

Pediatric acute onset neuropsychiatric syndrome

Authorization may be granted when the patient has a diagnosis of pediatric acute onset neuropsychiatric syndrome.

Autoimmune encephalitis

Authorization may be granted when the patient has a diagnosis of autoimmune encephalitis.

Approval Duration and Quantity Restrictions:

Approval: 6 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

♥aetna[™] **AETNA BETTER HEALTH®** Coverage Policy/Guideline Name: **Rituximab Products** 2 of 2 Page: 3/1/2024 Effective Date: Last Review Date: 2/29/2024 □Florida □Illinois \Box Florida Kids Applies □New Jersey ⊠Maryland □Michigan to: □Kentucky PRMD □ Pennsylvania Kids □ Pennsylvania

References:

1. Maryland Senate Bill 475. May 2020.